Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: GlobeNewswire
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the company will present preclinical data from its selective WEE1 inhibitor azenosertib at the European Society of Medical Oncology (ESMO) 2024 Congress, occurring September 13-17 in Barcelona, Spain. “The confluence of DNA damage induced by TOP1 inhibitors and cell cycle deregulation and genomic instability induced by azenosertib provides a mechanistic rationale for this combination, as well as more broadly with antibody drug conjugates (ADCs) utilizing these inhibitors as payloads,” said Mark Lackner, PhD, Chief Scientific Officer. “The preclinical data demonstrated this synergistic effect and suggest that azenosertib in combination with ADCs could be an important therapeutic approach in
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLPR Newswire
- Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTLAccesswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLPR Newswire
- ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing InvestigationAccesswire
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ZNTL
Earnings
- 11/12/24 - Beat
ZNTL
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form 4
- 2/11/25 - Form 144
- ZNTL's page on the SEC website